Shares of ValiRx plc (LON:VAL – Get Free Report) traded up 14.5% during mid-day trading on Tuesday . The stock traded as high as GBX 1.80 ($0.02) and last traded at GBX 1.78 ($0.02). 568,408 shares were traded during mid-day trading, a decline of 45% from the average session volume of 1,025,416 shares. The stock had previously closed at GBX 1.55 ($0.02).
ValiRx Price Performance
The stock has a market capitalization of £2.36 million, a price-to-earnings ratio of -79.75 and a beta of 0.59. The company has a debt-to-equity ratio of 0.49, a quick ratio of 1.27 and a current ratio of 6.65. The company has a 50 day moving average of GBX 1.62 and a 200 day moving average of GBX 2.31.
About ValiRx
ValiRx plc, a biopharmaceutical company, engages in the development of oncology therapeutics and companion diagnostics in the United Kingdom. The company's lead drug candidates include VAL201, a short peptide that has completed Phase I/II trials for the treatment of prostate cancer; and VAL401, a reformulation of anti-psychotic drug risperidone, which has completed Phase II clinical trial for the treatment of end-stage non-small cell lung cancer.
Featured Articles
- Five stocks we like better than ValiRx
- Best of the list of Dividend Aristocrats: Build wealth with the aristocrat index
- Is Monolithic Power Systems a Screaming Buy After Near 40% Drop?
- Why Invest in High-Yield Dividend Stocks?
- Applied Materials Market Capitulates: Now is the Time to Buy
- How Technical Indicators Can Help You Find Oversold Stocks
- 3 Ultra-High Dividend Yield Stocks for the New Year
Receive News & Ratings for ValiRx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ValiRx and related companies with MarketBeat.com's FREE daily email newsletter.
